Integer Holdings (ITGR) Company Overview

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR) and Edwards Lifesciences (EW). But which of these two stocks is more attractive to value investors?

PLANO, Texas, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), will join innovators and industry leaders around the world in exhibiting at MD&M West, Feb. 4 – 6, 2025, at the Anaheim Convention Center in Anaheim, California. Integer welcomes visitors to booth #1439 to learn more about the company's commitment to customers as their partner of choice in enhancing the lives of patients through access to innovative technologies, superior quality and dependable manufacturing to accelerate speed to market and reduce product development risk.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Integer (ITGR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

PLANO, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the “Notes”) that the Notes are convertible, at the option of the holders (the “Conversion Option”) beginning on January 1, 2025, and ending at the close of business on March 31, 2025. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company's common stock or a combination thereof, at the Company's election, in respect of the remainder, if any, of the Company's conversion obligation in excess of the aggregate principal amount of the Notes being converted. Any determination regarding the convertibility of the Notes during future periods will be made in accordance with the terms of the Indenture governing the Notes.

ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.

ITGR shares gain on the back of growth in the Medical segment. However, dependence on third-party suppliers is concerning.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.